These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15569670)

  • 1. Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.
    Unwin RD; Sternberg DW; Lu Y; Pierce A; Gilliland DG; Whetton AD
    J Biol Chem; 2005 Feb; 280(8):6316-26. PubMed ID: 15569670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
    Beissert T; Puccetti E; Bianchini A; Güller S; Boehrer S; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
    Blood; 2003 Oct; 102(8):2985-93. PubMed ID: 12829585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X; Layton JE; Elefanty A; Lieschke GJ
    Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.
    Weisberg E; Griffin JD
    Blood; 2000 Jun; 95(11):3498-505. PubMed ID: 10828035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
    Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
    Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events.
    Kim H; Gillis LC; Jarvis JD; Yang S; Huang K; Der S; Barber DL
    BMC Cancer; 2011 Dec; 11():528. PubMed ID: 22204395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells.
    Komatsu N; Watanabe T; Uchida M; Mori M; Kirito K; Kikuchi S; Liu Q; Tauchi T; Miyazawa K; Endo H; Nagai T; Ozawa K
    J Biol Chem; 2003 Feb; 278(8):6411-9. PubMed ID: 12456669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
    Parmar S; Katsoulidis E; Verma A; Li Y; Sassano A; Lal L; Majchrzak B; Ravandi F; Tallman MS; Fish EN; Platanias LC
    J Biol Chem; 2004 Jun; 279(24):25345-52. PubMed ID: 15056660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
    Carroll M; Ohno-Jones S; Tamura S; Buchdunger E; Zimmermann J; Lydon NB; Gilliland DG; Druker BJ
    Blood; 1997 Dec; 90(12):4947-52. PubMed ID: 9389713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.
    Chen J; Wall NR; Kocher K; Duclos N; Fabbro D; Neuberg D; Griffin JD; Shi Y; Gilliland DG
    J Clin Invest; 2004 Jun; 113(12):1784-91. PubMed ID: 15199413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of leukaemogenic tyrosine kinases on cell motility is governed by subcellular localisation.
    Pierce A; Lu Y; Hamzah HG; Thompson S; Owen-Lynch PJ; Whetton AD; Spooncer E
    Br J Haematol; 2006 May; 133(3):345-52. PubMed ID: 16643438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
    Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.
    van der Kuip H; Goetz AW; Miething C; Duyster J; Aulitzky WE
    Blood; 2001 Sep; 98(5):1532-41. PubMed ID: 11520804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.
    Schuster C; Forster K; Dierks H; Elsasser A; Behre G; Simon N; Danhauser-Riedl S; Hallek M; Warmuth M
    Blood; 2003 Jan; 101(2):655-63. PubMed ID: 12393654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
    Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
    Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
    Stover EH; Chen J; Lee BH; Cools J; McDowell E; Adelsperger J; Cullen D; Coburn A; Moore SA; Okabe R; Fabbro D; Manley PW; Griffin JD; Gilliland DG
    Blood; 2005 Nov; 106(9):3206-13. PubMed ID: 16030188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.